Therachon is a global biotechnology company, focused on developing treatments for rare, genetic diseases that currently have no available treatments. We are committed to the community, caregivers and advancing research to transform the lives of people with unmet medical needs. We are deeply committed to fostering a community that is rigorous about science and passionate about making a difference by translating the promise of our science into new treatments for patients.
08.05.2019
Pfizer Acquires Therachon for up to $810 million (startupticker.ch)
21.01.2019
Biotech startups strengthen their teams for the next steps (startupticker.ch)
05.12.2018
EU grants Therachon Orphan Drug Designation (startupticker.ch)
10.10.2018
Therachon evolves to a multi-asset rare disease company (startupticker.ch)
09.08.2018
Therachon Raises $60 Million Mezzanine Financing (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Website:
therachon.com/
Headquarter:
Basel
Foundation Date:
January 2016
Technology:
Sectors: